Biomarin Pharmaceutical (BMRN) Return on Invested Capital (2012 - 2025)

Biomarin Pharmaceutical's Return on Invested Capital history runs 13 years deep, the most recent figure standing at 0.01% for Q1 2025.

• Quarterly Return on Invested Capital changed 0.0% year-over-year to 0.01% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 0.01% (changed 0.0% YoY) and the FY2023 annual result came in at 0.01%, down 4.0% from the prior year.
• Return on Invested Capital was 0.01% for Q1 2025 at Biomarin Pharmaceutical, up from 0.0% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.05% in Q3 2023 and bottomed at 0.01% in Q4 2021.
• A 5-year average of 0.01% and a median of 0.01% in 2022 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2023 — Return on Invested Capital advanced 4 bps — and 2024, when it fell 4 bps.
• Biomarin Pharmaceutical's Return on Invested Capital stood at 0.01% in 2021, then jumped by 291 bps to 0.01% in 2022, then tumbled by 34 bps to 0.01% in 2023, then slumped by 52 bps to 0.0% in 2024, then soared by 110 bps to 0.01% in 2025.
• Business Quant data shows BMRN's Return on Invested Capital at 0.01% in Q1 2025, 0.0% in Q4 2024, and 0.0% in Q3 2024.